

Our Vision

We strive to be a leading enterprise in the global pharmaceutical and healthcare markets.

Our Mission

Better health for families worldwide.

Contents

02	Introduction
04	Chairman's Report
05	Management Report
43	Financial Statements
50	Notes to the Financial Statements
51	Statement of Directors
52	Statement of Directors (continued)
54	Statement of Directors (continued)
56	Statement of Directors (continued)
58	Statement of Directors (continued)
91	Appendix

Corporate

Directors

Executive Director

吳以芳 (Wu Yifang)
()

Non-executive Directors

陳啟宇 (Chen Qiyu)
姚方 (Yao Fang)
徐曉亮 (Xu Xiaoliang)
龔平 (Gong Ping)
潘東輝 (Pan Donghui)
張厚林 (Zhang Houlin)

Independent Non-executive Directors

李玲 (Li Ling)
湯谷良 (Tang Guliang)
王全弟¹ (Wang Quandi)
余梓山¹ (Yu Zishan)
江憲² (Jiang Xian)
黃天祐² (Huang Tianyou)

Supervisors

任倩 (Ren Qian)
曹根興 (Cao Genxing)
管一民 (Guan Yimin)

Joint Company Secretaries

董曉嫻 (Dong Xiaoyan)
甘美霞 (Gan Meixia)

Authorized Representatives

吳以芳 (Wu Yifang)
甘美霞 (Gan Meixia)

Strategic Committee

陳啟宇 (Chen Qiyu)
吳以芳 (Wu Yifang)
姚方 (Yao Fang)
徐曉亮 (Xu Xiaoliang)
李玲 (Li Ling)

Audit Committee

湯谷良 (Tang Guliang)
王全弟¹ (Wang Quandi)
龔平 (Gong Ping)
江憲² (Jiang Xian)

Nomination Committee

王全弟¹ (Wang Quandi)
李玲 (Li Ling)
潘東輝 (Pan Donghui)
江憲² (Jiang Xian)

Remuneration and Appraisal Committee

余梓山¹ (Yu Zishan)
湯谷良 (Tang Guliang)
王全弟¹ (Wang Quandi)
陳啟宇 (Chen Qiyu)
潘東輝 (Pan Donghui)
江憲² (Jiang Xian)
黃天祐² (Huang Tianyou)

Environmental, Social and Governance Committee

余梓山¹ (Yu Zishan)
李玲 (Li Ling)
吳以芳 (Wu Yifang)
黃天祐² (Huang Tianyou)

Registered Office

10
2000 3, n

Principal Place of Business in the PRC

12
200233, n

¹ 11 2021
² 11 2021

Principal Place of Business in Hong Kong

Unit 4, Level 13, Block 1, Kowloon Bay

Legal Advisers in Hong Kong

Deacons

Legal Advisers in the PRC

Wang & Partners (P.R.C.)

Auditors

PricewaterhouseCoopers

Principal Banks

Bank of China Limited
 Citibank
 HSBC Bank plc
 Industrial and Commercial Bank of China Limited
 Standard Chartered Bank

Company Name

China Resources Gas Corporation Limited (Incorporated in Hong Kong)*

Stock Abbreviation

CRG

Share Listing

China Resources Gas Corporation Limited
 001
 China Resources Gas Corporation Limited
 021

A Share Registrar and Transfer Office in the PRC

China Resources Gas Corporation Limited & China Resources Gas Corporation Limited (Incorporated in Hong Kong)
 1111
 China Resources Gas Corporation Limited

H Share Registrar and Transfer Office in Hong Kong

China Resources Gas Corporation Limited
 Unit 4, Level 13, Block 1, Kowloon Bay

Company's Website

http://www.crg.com.hk

Financial

0.0.

For the six months ended 30 June

	2021 RMB million	2020 "
Operating results		
Revenue	16,878	13,422
Cost of sales	(8,767)	(7,114)
Gross profit	1,343	1,222
Operating expenses	(3,304)	(2,302)
Operating profit	2,482	1,111
Finance income	4,670	3,111
Profitability		
Operating profit margin	51.94%	4.4%
Operating profit margin excluding pharmaceutical manufacturing segment	7.96%	.2%
Operating profit margin excluding pharmaceutical manufacturing segment and finance income	16.32%	13.1%
Earnings per share ()		
Operating profit	0.97	0.4
Operating profit excluding pharmaceutical manufacturing segment	0.97	0.1
Of which: Pharmaceutical manufacturing segment		
Revenue	12,179	10,212
Cost of sales	7,072	5,111
Gross profit	1,353	1,111
Operating expenses	1,257	1,111

	30 June 2021 RMB million	31 2020 "
Assets		
Property, plant and equipment	88,422	83,212
Intangible assets	37,804	33,311
Investments in subsidiaries	41,383	33,022
Investments in associates	10,489	10,211
Goodwill	46.80%	4.0%



FINANCIAL REVIEW

... ..

... ..

... .. 20.8%.

... ..

2,482 " 44.3%.

1,0 " 1.1%.

... .. 1.2 "

... .. 3.1%.

... .. 2.3%.

... .. (1)

... .. (... ..), (... ..)

... .. (2)

... .. 44.8%

... .. 2020.

REVENUE

... ..

... .. 20.8%.

... .. 11,80 "

... .. 1.1 "

... .. 30.0%.

... .. 12,1 "

... .. 22.3%.

... .. 1,33 "

... .. 21.24%.

... .. 1,2 " (... ..)

... .. (... ..) 12.4%

COST OF SALES

... .. 30.4% 1,111 " 21 "

... .. 2020.

GROSS PROFIT

... .. 13.14%

... .. 4 " 2020.

... .. 2020 1.4% 4%.

Management

SELLING AND DISTRIBUTION EXPENSES

During the reporting period, the Company's selling and distribution expenses were RMB 43 million, an increase of 104.4% over the same period in 2020.

R&D EXPENSES AND R&D EXPENDITURE

During the reporting period, the Company's R&D expenses and R&D expenditure were RMB 1,432 million, an increase of 1.1% over the same period in 2020. The Company's R&D expenses were RMB 1,233 million, an increase of 2.3% over the same period in 2020. The Company's R&D expenditure was RMB 23 million, an increase of 1.31% over the same period in 2020. The Company's R&D expenditure was RMB 30.5%, an increase of 11.31% over the same period in 2020. The Company's R&D expenditure was RMB 32 million, an increase of 1.3% over the same period in 2020.

SHARE OF PROFITS OF ASSOCIATES

During the reporting period, the Company's share of profits of associates was RMB 2 million, a decrease of 32.4% over the same period in 2020.

PROFIT FOR THE PERIOD

During the reporting period, the Company's profit for the period was RMB 2,441 million, an increase of 44.1% over the same period in 2020. The Company's profit for the period was RMB 1,100 million, an increase of 1.32% over the same period in 2020. The Company's profit for the period was RMB 13.1%, an increase of 13.1% over the same period in 2020.

PROFIT FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

During the reporting period, the Company's profit for the period attributable to owners of the parent was RMB 2,442 million, an increase of 44.1% over the same period in 2020. The Company's profit for the period attributable to owners of the parent was RMB 1,100 million, an increase of 1.32% over the same period in 2020. The Company's profit for the period attributable to owners of the parent was RMB (1) million, an increase of (1) million over the same period in 2020. The Company's profit for the period attributable to owners of the parent was RMB (2) million, an increase of (2) million over the same period in 2020.

DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

Total Debts

As at 30 June 2021, the total debt of the Group was 2,213 million HK dollars (2020: 23,433 million HK dollars), of which 30.3% was denominated in US dollars (2020: 31.34%).

As at 30 June 2021, the total debt of the Group was 42 million HK dollars (2020: 11 million HK dollars).

As at 30 June 2021, the total debt of the Group was 3,220 million HK dollars (2020: 4,448 million HK dollars).

30 June
2021

31

2020

Cash and cash equivalents denominated in:

	30 June 2021	31 2020
Cash	7,269	,214
Short-term deposits	164	2,14
Accounts receivable	2,564	2,30
Other receivables	72	41
Other	420	20
Total	10,489	, 2

Gearing Ratio

As at 30 June 2021, the gearing ratio of the Group was 2.1% (2020: 2.3%).

Interest Rate

As at 30 June 2021, the interest rate of the Group was 10.3% (2020: 11.03%).

Management

Maturity Structure of Outstanding Debts

	30 June 2021	31 2020
1	15,992	14,40
2	2,847	0,01
3	4,564	4
4	1,810	4
	25,213	23,43

Available Facilities

30 June 2021, available facilities	10,4
30 June 2020, available facilities	0,1
30 June 2021, available facilities	1,41

Collateral and Pledged Assets

30 June 2021, collateral and pledged assets	1,1
30 June 2020, collateral and pledged assets	2
30 June 2021, collateral and pledged assets	4
30 June 2020, collateral and pledged assets	4
30 June 2021, collateral and pledged assets	1
30 June 2020, collateral and pledged assets	(31)

	Revenue		2020		2021
	Jan – Jun 2021	Percentage of revenue (%)	2020	2020	
	Amount		2020	2020	
			(%)	(%)	(%)
By business segment					
Construction	12,179	72.16	12,179	22.3	22.3
Services ()	2,832	16.78	2,832	5.31	5.31
Other	1,843	10.92	1,843	3.38	3.38
By geographical locations					
China	11,680	69.20	11,680	21.0	21.0
Other	5,198	30.80	5,198	9.6	9.6

Revenue for the period ended 30 June 2021, compared to 12,179 million RMB for the period ended 30 June 2020, increased by 14.2%.

Segment Performance Overview

The revenue for the period ended 30 June 2021, compared to 12,179 million RMB for the period ended 30 June 2020, increased by 14.2%. The revenue for the period ended 30 June 2021, compared to 12,179 million RMB for the period ended 30 June 2020, increased by 14.2%.

Management

... (), ... () ...
 ... (1) ...
 24 " ... 223.21%
 () ...
 2020, 32 " 20 " (2)
 ... 32.0% ...
 (3) (-1) ...
 ... 00 "
 (4) ...
 0.0% ...

Major therapeutic area	Jan – Jun 2021	2020*	(%)
(1, 7)	1,705	4	2 .
(2, 7)	1,415	1,	1 . 2
(3, 7)	2,656	1,2	4 .30
(4, 7)	616		1 .41
(5, 7)	1,024	1,24	1 .
(6, 7)	577	4 2	2 .

- 1 ... 2 . %, ...
- 2 ... 1 . 2%, ...
- 3 ... 4 .30%, ...
- 4 ... 1 .41%, ...
- 5 ... 1 . %, ...

6. ... 2. %, ...

7. ...

...

...

...

...

...

* ... 2020 ... 2021, ... 2020

& ... 2020 ... 2,00 & ... 1,400 ... 240 ... 10 ... 20 ... 3

... () ... -1 ... 1 2 2 ... () ...

... -1 ... 2021 ...

0% ...

Table 1 — Major pipeline drug projects

Type	Number	Remarks
	2	/
	30	2.
	2	3. 1
	13	4. 1
	1 [§]	3
	103	/
	20	/
	3 [§]	/
		/
	240	/

1 ...

2 ... (奕凱達) ...

Table 2 — Small molecular innovative drugs under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period	R&D progress in other countries as at the end of the Reporting Period
1	抗肿瘤	-1 [§]	肝癌	临床三期	临床三期 (美国)
2		-1 01	肝癌	临床三期	
3		-1 01	肝癌	临床三期	临床三期 (美国)
4		-1	肝癌	临床三期	
		-1	肝癌	临床三期	临床三期 (美国)
		1001	肝癌	临床三期	临床三期 (美国)
		-4	肝癌	临床三期	
§		-011	肝癌	临床三期	
		-33 [§]	肝癌	临床三期	临床三期 (美国)
10		-43	肝癌	临床三期	临床三期 (美国)
11		-0 [§]	肝癌	临床三期	
12		01001	肝癌	临床三期	
13		-20 [§]	肝癌	临床三期	
14	抗肿瘤	-11	肝癌	临床三期	
1		-20	肝癌	临床三期	
1	抗肿瘤	103	肝癌		临床三期 (美国)
1		-2	肝癌	临床三期	

Management

Table 4 — License-in innovative drugs

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period
1	1. 抗肿瘤药	1. 1. 1.	1. 1. 1. (-)	n. 1. 1. 1.
2		1. 1. 2.	1. 1. 2. (-)	n. 1. 1. 1.
3	2. 抗肿瘤药	2. 1. 1.	2. 1. 1. (-)	n. 1. 1. 1.
4		2. 1. 2.	2. 1. 2. (-)	n. 1. 1. 1.
	3. 抗肿瘤药	3. 1. 1.	3. 1. 1. (-)	n. 1. 1. 1.
		3. 1. 2.	3. 1. 2. (-)	n. 1. 1. 1.
	4. 抗肿瘤药	4. 1. 1.	4. 1. 1. (-)	n. 1. 1. 1.
		4. 1. 2.	4. 1. 2. (-)	n. 1. 1. 1.
	5. 抗肿瘤药	5. 1. 1.	5. 1. 1. (-)	n. 1. 1. 1.
		5. 1. 2.	5. 1. 2. (-)	n. 1. 1. 1.
9	6. 抗肿瘤药	6. 1. 1.	6. 1. 1. (-)	n. 1. 1. 1.
		6. 1. 2.	6. 1. 2. (-)	n. 1. 1. 1.
10	7. 抗肿瘤药	7. 1. 1.	7. 1. 1. (-)	n. 1. 1. 1.
11		7. 1. 2.	7. 1. 2. (-)	n. 1. 1. 1.
12	8. 抗肿瘤药	8. 1. 1.	8. 1. 1. (-)	n. 1. 1. 1.
13		8. 1. 2.	8. 1. 2. (-)	n. 1. 1. 1.

Table 5 — Biosimilars under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period
1	-	... (, 04)	... () ... " "	...
2		n ... (, 0)	... () ... n ... " ()	...
3		- 2 ... (, 11)	... ()	n. ...
4		- 2 ... (, 12)	... (), ... () ... " " ... ()	n. ...
		- 4 ... (, 13)	... () ... ()	...
		- 6 ... (, 14)	... ()	n. ...
		- 3 ... (, 1)	... ()	...
10	...			
11		... (0)		n. ...
12				n. ...
13	...	n ... (,,)	...	n. ...
14		n ... (,,)		...

Table 7 — Products won tenders for centralized procurement

No.	Round selected	Name of drugs	Indications	Specifications	Packaging specification (/)	Selected price (/)	Selected quantity ('000 /)
1	4+					0.4	2,13
2				10		2.5	1,00
3	n			0.2		.3	2,
4				0.1	10	1.4	4
					0.2	10	0.
				0.1	100	.02	4,2 1
	n n			40	1	1.4	4,
				0.1	30	33.	12, 00
				2	14	10.0	2,21
10				0.2	0	.03	,3 2
11				10	14	1.2	44
12	n n			40	32	1.1	, 00
13				10	10	1.1	
14			1. 2. n , 3. n 4. n	0.	30	20.40	,3 .
1				0.2	30	.00	1
1				20	0	.0	2,10
1			0.2	100	1.4	,4	
1	n n		1. n 2. n	0.2	30	3.0	,300
1			1. 0 2.1 0	0.	14	1 2. 3	3 0

Management

.....

.....

.....

Management

Management Discussion and Analysis

	2021	2020	2021	2020
Operating profit	2,332	2,032	114.8%	100.0%
Operating profit margin	14.0%	13.7%	4.4%	4.1%
Net profit	1,434	1,234	116.2%	100.0%
Net profit margin	14.2%	13.8%	4.4%	4.1%
Basic earnings per share	24.3	21.5	112.6%	100.0%
Diluted earnings per share	24.2	21.4	113.1%	100.0%
Dividend per share	12.0	12.0	100.0%	100.0%
Dividend yield	49.8%	56.1%	-12.5%	-11.2%
Return on equity	12.0%	11.8%	2.0%	1.9%
Return on assets	8.0%	7.8%	2.2%	2.1%
Operating profit	\$12	\$10	20%	100%
Net profit	\$1	\$1	0%	100%

Management

... 2021, ... 24,120 ... ,02 ...
 ... 3,13 ... 22.2 %, 2.1% ... 23.3%
 ... 4,32 ...
 ... * (深圳恒生醫院), ...

... 2021, ... 12 ...
 ... 4 ...
 ... 2021, ... 20.2%
 ... 1,044 ...

... 2021, ... 24,120 ... ,02 ...
 ... 3,13 ... 22.2 %, 2.1% ... 23.3%

... 2021, ... 20.2%
 ... 1,044 ...

... 2021, ... 4,10 ...
 ... 33.1 %.

... 2021, ... 2. ... 2021, ...
 ... 13,22 ... 24. %

Management

Financing

During the reporting period, the Group's financing activities were as follows:

Item	2021, million RMB	2020, million RMB
Issuance of bank loans	1,111	1,322
Repayment of bank loans	(421)	(421)
Repayment of bank deposits	(1,000)	(1,411)
Repayment of bank deposits	(2,400)	(2,300)
Repayment of bank deposits	(0)	(12)
Other financing activities	200	(100)
Net increase/decrease in cash and cash equivalents	(2,090)	(2,922)

2. Major Operations in the Reporting Period

A. Analysis on Principal Operations

(1)

Items	Amount for the period	Amount for the corresponding period of last year	Period-on-period change (%)
Operating income	1,111	13,21	20.4
Operating expenses	4,3	3,31	10.4
Operating profit	1,0	1,322	13.4
Other income & expenses	1,2	1,204	2.3
Profit before tax	421	42	1.4
Income tax expense	1,0	1,41	1.1
Net profit	2,40	2,3	2.1
Net profit attributable to shareholders of the Company	0	12	0.4

1. Operating income: The increase in operating income is mainly due to the increase in sales volume and price.

2. Operating expenses: The increase in operating expenses is mainly due to the increase in sales and administrative expenses.

3. Profit before tax: The increase in profit before tax is mainly due to the increase in operating profit and other income.

(2) &

&

	2021	2020	2019
&	1, 2		
&	3 2		
&	1, 4		
&	11. 3		
&	14. 1		
&	20.0		

B. Segment and Regional Operations

(1)

By segments	Principal operations by segments			Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
	Revenue	Cost of sales	Gross profit margin (%)			
n	12,1	,10	,0	22.3	3 .04	. 4.21
n	2,32	1,40	4 . 4	.31	13.0	. 2.
n	1,43	1, 11	1,01	3 . 1	33. 2	. 1.1

Principal operations by products

By products	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
1. Chemical products	1,033.3	333.3	67.4	2.1	20.4	3.4
2. Biological products	1,411.1	233.3	83.4	1.2	1.0	4.2
3. Medical devices	2,111.1	1,111.1	47.2	4.30	1.4	2.21
4. Others	1,111.1	43.3	96.1	1.41	10.42	0.2
Total	1,024.0	402.0	41.21	1.1	24.3	20.01
		423.3	2.1	2.1	2.1	0.2

Principal operations by geographical locations

By geographical locations	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
1. China	11,110.0	2,111.1	4.2	1.0	2.22	3.1
2. Overseas	1,111.1	2,111.1	4.1	2.1	32.3	2.13
Total	12,221.1	4,222.2	4.1	2.1	32.3	2.13
1. China	11,110.0	2,111.1	4.2	1.0	2.22	3.1
2. Overseas	1,111.1	2,111.1	4.1	2.1	32.3	2.13
3. China	11,110.0	2,111.1	4.2	1.0	2.22	3.1
4. Overseas	1,111.1	2,111.1	4.1	2.1	32.3	2.13
5. China	11,110.0	2,111.1	4.2	1.0	2.22	3.1
6. Overseas	1,111.1	2,111.1	4.1	2.1	32.3	2.13
7. China	11,110.0	2,111.1	4.2	1.0	2.22	3.1
8. Overseas	1,111.1	2,111.1	4.1	2.1	32.3	2.13

C. Subsidiaries and Investees
(1)

Company name	Nature of business	Major products or services	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
...	1	,12	4,20	2, 1	430	3 ⁵
...	4 2	,4 3	3,044	3,343	34	31 ⁵
...	/	1,4	,102	1,03	1 ⁵	4 1

Company name	Nature of business	Major products	Registered capital	Total assets	Net assets	Revenue	Net profit
...	10	2, 2	2,02	14	4
...	43	, 30	2, 1	34	3 4
...	0	3,0 ⁵ 0	1, 3	00	103
...	/	2, 44	2,223	11	112

E. Employees and Remuneration Policies

As of the end of 2021, the total number of employees was 34,300, an increase of 1,000 from the end of 2020. The number of employees in the pharmaceutical business segment was 28,000, an increase of 1,000 from the end of 2020. The number of employees in the chemical business segment was 6,300, an increase of 0 from the end of 2020.

3. Outlook for Operations in the Second Half of 2021

A. Competition and Development Trends of the Industry

In 2021, the pharmaceutical industry continues to face a complex and changing external environment. On the one hand, the global economic recovery is uneven, and the impact of the COVID-19 pandemic is still significant. On the other hand, the industry is undergoing a period of rapid transformation and upgrading, with the emergence of new technologies and products. The industry is expected to continue to grow, but the competition will be more intense.

The pharmaceutical industry is expected to continue to grow, but the competition will be more intense. The industry is expected to continue to grow, but the competition will be more intense.

In 2021, the pharmaceutical industry continues to face a complex and changing external environment. On the one hand, the global economic recovery is uneven, and the impact of the COVID-19 pandemic is still significant. On the other hand, the industry is undergoing a period of rapid transformation and upgrading, with the emergence of new technologies and products. The industry is expected to continue to grow, but the competition will be more intense.

The pharmaceutical industry is expected to continue to grow, but the competition will be more intense. The industry is expected to continue to grow, but the competition will be more intense.

* (蘇州開拓藥業股份有限公司)

The pharmaceutical industry is expected to continue to grow, but the competition will be more intense. The industry is expected to continue to grow, but the competition will be more intense.

In 2021, the pharmaceutical industry continues to face a complex and changing external environment. On the one hand, the global economic recovery is uneven, and the impact of the COVID-19 pandemic is still significant. On the other hand, the industry is undergoing a period of rapid transformation and upgrading, with the emergence of new technologies and products. The industry is expected to continue to grow, but the competition will be more intense.

Management

Management Discussion and Analysis

2021, the Company's operating performance is as follows:

2021, the Company's operating performance is as follows:

2021, the Company's operating performance is as follows:

2021, the Company's operating performance is as follows:

Management

4. Potential Risks

A. Risks in relation to industry policies and system reforms

The pharmaceutical industry is subject to various industry policies and system reforms, which may have a significant impact on the company's business operations. The company has established a risk management system to identify, assess, and mitigate these risks. The following table provides a detailed overview of the risks and the company's corresponding management strategies.

Risk Category	Risk Description	Management Strategy
Policy Changes	Changes in industry policies, such as drug pricing regulations, may lead to a decrease in product prices and revenue.	The company will actively monitor policy changes and engage in communication with regulatory authorities to understand the impact and seek solutions.
System Reforms	System reforms, such as the implementation of a new drug evaluation system, may increase the time and cost of drug development.	The company will strengthen its R&D capabilities and optimize the drug development process to improve efficiency.
Market Access	Changes in market access policies may affect the company's ability to enter new markets.	The company will focus on building strong relationships with local regulatory authorities and distributors to ensure market access.
Competition	Increased competition from domestic and international pharmaceutical companies may lead to a decrease in market share.	The company will continue to invest in R&D to develop innovative products and improve its marketing and sales strategies.

... (1) ... (2) ... (3) ... (4) ... (5) ... (6) ... (7) ... (8) ... (9) ... (10) ... (11) ... (12) ... (13) ... (14) ... (15) ... (16) ... (17) ... (18) ... (19) ... (20) ... (21) ... (22) ... (23) ... (24) ... (25) ... (26) ... (27) ... (28) ... (29) ... (30) ... (31) ... (32) ... (33) ... (34) ... (35) ... (36) ... (37) ... (38) ... (39) ... (40) ... (41) ... (42) ... (43) ... (44) ... (45) ... (46) ... (47) ... (48) ... (49) ... (50) ... (51) ... (52) ... (53) ... (54) ... (55) ... (56) ... (57) ... (58) ... (59) ... (60) ... (61) ... (62) ... (63) ... (64) ... (65) ... (66) ... (67) ... (68) ... (69) ... (70) ... (71) ... (72) ... (73) ... (74) ... (75) ... (76) ... (77) ... (78) ... (79) ... (80) ... (81) ... (82) ... (83) ... (84) ... (85) ... (86) ... (87) ... (88) ... (89) ... (90) ... (91) ... (92) ... (93) ... (94) ... (95) ... (96) ... (97) ... (98) ... (99) ... (100) ...

C. Business and operating risks

(1) &

... (1) ... (2) ... (3) ... (4) ... (5) ... (6) ... (7) ... (8) ... (9) ... (10) ... (11) ... (12) ... (13) ... (14) ... (15) ... (16) ... (17) ... (18) ... (19) ... (20) ... (21) ... (22) ... (23) ... (24) ... (25) ... (26) ... (27) ... (28) ... (29) ... (30) ... (31) ... (32) ... (33) ... (34) ... (35) ... (36) ... (37) ... (38) ... (39) ... (40) ... (41) ... (42) ... (43) ... (44) ... (45) ... (46) ... (47) ... (48) ... (49) ... (50) ... (51) ... (52) ... (53) ... (54) ... (55) ... (56) ... (57) ... (58) ... (59) ... (60) ... (61) ... (62) ... (63) ... (64) ... (65) ... (66) ... (67) ... (68) ... (69) ... (70) ... (71) ... (72) ... (73) ... (74) ... (75) ... (76) ... (77) ... (78) ... (79) ... (80) ... (81) ... (82) ... (83) ... (84) ... (85) ... (86) ... (87) ... (88) ... (89) ... (90) ... (91) ... (92) ... (93) ... (94) ... (95) ... (96) ... (97) ... (98) ... (99) ... (100) ...

Management

B. The Mandate to Issue Inter-bank Market Debt Financing Instruments

On 2021, the Company obtained a mandate to issue inter-bank market debt financing instruments with a total amount of RMB 1.2 billion. The interest rate of the mandate is 3.10%.

On 2021, the Company obtained a mandate to issue inter-bank market debt financing instruments with a total amount of RMB 1.2 billion. The interest rate of the mandate is 2.0%.

C. The Public Issuance of Corporate Bonds to Qualified Investors

On 2021, the Company obtained a mandate to issue corporate bonds to qualified investors with a total amount of RMB 1.2 billion. The interest rate of the mandate is 3.1%.

D. Proposed non-public issuance of A shares

On 2020, the Company proposed a non-public issuance of A shares with a total amount of RMB 1.2 billion. The interest rate of the mandate is 3.1%.

On 2021, the Company proposed a non-public issuance of A shares with a total amount of RMB 1.2 billion. The interest rate of the mandate is 3.1%.

On 2021, the Company proposed a non-public issuance of A shares with a total amount of RMB 1.2 billion. The interest rate of the mandate is 3.1%.

E. 2021 Restricted Share Incentive Scheme

On 2021, the Company proposed a restricted share incentive scheme with a total amount of RMB 1.2 billion. The interest rate of the mandate is 3.1%.

RESULTS AND DIVIDENDS

	30 June 2021	30 June 2020
Profit after tax	1,000,000	1,000,000
Dividend per share	0.00	0.00

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

	30 June 2021	30 June 2020
Number of shares purchased	0	0
Number of shares sold	0	0
Number of shares redeemed	0	0

DIRECTORS

The following table sets out the names of the directors of the Company who served during the period from 1 January 2021 to 30 June 2021.

Executive Director

Ms. Wu Yifang (吳以芳) (Executive Director)

Non-executive Directors

- Mr. Chen Qiyu (陳啟宇)
- Ms. Yao Fang (姚方)
- Mr. Xu Xiaoliang (徐曉亮)
- Mr. Gao Ping (龔平)
- Mr. Pan Donghui (潘東輝)
- Mr. Zhang Houlin (張厚林)

Independent Non-executive Directors

- Ms. Li Ling (李玲)
- Mr. Tang Yuliang (湯谷良)
- Mr. Wang Quanyang (王全弟)
- Mr. Yu Zishan (余梓山)

	11 June 2021	11 June 2020
Number of shares purchased	0	0
Number of shares sold	0	0
Number of shares redeemed	0	0

Statutory

SUPERVISORS

任倩 (Ren Qian) (任倩) (曹根興) (Cao Genxing) (曹根興) (管一民) (Guan Yimin) (管一民)

CHANGE OF INFORMATION OF DIRECTORS AND SUPERVISORS

2021年10月10日 (October 10, 2021)

北京三元食品股份有限公司 (Beijing Sanyuan Food Co., Ltd.) (0042) 2021年10月21日 (October 21, 2021)

上海百聯集團股份有限公司 (Shanghai Bailian Group Co., Ltd.) (0052) 2021年11月14日 (November 14, 2021)

2021年11月11日 (November 11, 2021)

2021年11月30日 (November 30, 2021) 2021年11月30日 (November 30, 2021)

2021年11月13日 (November 13, 2021)

SHARE INCENTIVE SCHEMES

Gland Pharma Share Option Incentive Scheme

2021年2月 (February 2021)

1,044 1.1%

Statutory

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 June 2021, the interests and short positions of the Directors, Supervisors and Chief Executive in the Shares, underlying Shares and debentures of the Company are as follows:

(1) Long positions in the Shares, underlying Shares and debentures of the Company

Name of Directors/ chief executive	Capacity	Class of Shares	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class of Shares
Mr. Zhang Zhong	Director	Ordinary Shares	342,000 ()	0.0 %
Mr. Zhang Zhong	Director	Ordinary Shares	1,000 ()	0.04%
Mr. Zhang Zhong	Director	Ordinary Shares	114,000 ()	0.01%
Mr. Zhang Zhong	Director	Ordinary Shares	4,330 ()	0.02%

(1) () represents 10,000 shares.

(2) Long positions in the shares, underlying shares and debentures of the Company's associated corporations (within the meaning of Part XV of the SFO)

Name of Directors/ chief executive	Name of associated corporation	Class of Shares	Capacity	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class of Shares
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	22,000 () ⁽²⁾	0.2 %
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	1,400 ()	0.00%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	40,000 () ⁽³⁾	0.01%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	20,000 () ⁽⁴⁾	0.24%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	2,320 ()	0.00%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	11,200,000 () ⁽¹⁾	0.13%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	1,000 ()	0.00%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	11,100,000 () ⁽¹⁾	0.13%
Mr. Zhang Zhong	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ordinary Shares	Director	11,100,000 () ⁽¹⁾	0.13%

(1) () represents 10,000 shares.

(2) 31 June 2021, 1,200,000 shares, 1,000,000 shares.

(3) 31 June 2021, 240,000 shares, 400,000 shares.

(4) 31 June 2021, 1,200,000 shares, 1,000,000 shares.

() 31 June 2021, 40,000 shares, 1,000,000 shares.

() 31 June 2021, 0,000 shares, 1,000,000 shares.

() 31 June 2021, 0,000 shares, 1,000,000 shares.

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES

As at 30 June 2021, the interests and short positions of substantial shareholders in the shares and underlying shares of the Company are as follows:

Name of Shareholders	Nature of interest	Class of Shares	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class of Shares
Mr. Liang Xiaohu	Beneficial	Ordinary	1,333,000	12.0%
Mr. Liang Xiaohu	Beneficial	Ordinary	3,020,000	4.0%
Mr. Liang Xiaohu	Beneficial	Ordinary	1,000,000	1.0%
Mr. Liang Xiaohu	Beneficial	Ordinary	1,333,000	12.0%
Mr. Liang Xiaohu	Beneficial	Ordinary	3,020,000	4.0%
Mr. Liang Xiaohu	Beneficial	Ordinary	1,333,000	14.0%
Mr. Liang Xiaohu	Beneficial	Ordinary	3,020,000	4.0%
Mr. Liang Xiaohu	Beneficial	Ordinary	1,333,000	14.0%
Mr. Liang Xiaohu	Beneficial	Ordinary	3,020,000	4.0%
Mr. Liang Xiaohu	Beneficial	Ordinary	1,333,000	14.0%
Mr. Liang Xiaohu	Beneficial	Ordinary	3,020,000	4.0%
Mr. Liang Xiaohu	Beneficial	Ordinary	114,000	0.01%
Mr. Liang Xiaohu	Beneficial	Ordinary	2,115,000	2.2%
Mr. Liang Xiaohu	Beneficial	Ordinary	1,220,000	0.23%
Mr. Liang Xiaohu	Beneficial	Ordinary	1,115,000	1.0%
Mr. Liang Xiaohu	Beneficial	Ordinary	43,000	1.02%
Mr. Liang Xiaohu	Beneficial	Ordinary	22,040,000	3.0%

(1) () represents () shares.

(2) Mr. Liang Xiaohu holds 1,333,000 shares, which represents 2.14% of the total shares of 62,300,000 shares of the Company. Mr. Liang Xiaohu also holds 3,020,000 shares, which represents 2.2% of the total shares of 137,272,727 shares of the Company.

(3) Mr. Liang Xiaohu holds 1,333,000 shares, which represents 2.14% of the total shares of 62,300,000 shares of the Company. Mr. Liang Xiaohu also holds 3,020,000 shares, which represents 2.2% of the total shares of 137,272,727 shares of the Company.

DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

None of the directors or supervisors of the Company has any rights to acquire shares or debentures of the Company.

Statutory

MODEL CODE FOR SECURITIES TRANSACTIONS

...

COMPLIANCE WITH THE CG CODE

...

...

2.1 ... 2020, ... (), 2004 ... 1 ... 2.1, ... () ... 2.1 ...

REVIEW OF INTERIM RESULTS AND INTERIM REPORT BY THE AUDIT COMMITTEE

11	2021, 000,000	-	11	2021, 000,000
000,000	000,000	000,000	000,000	000,000
000,000	000,000	000,000	000,000	000,000

Interim Condensed Consolidated

Interim Condensed Consolidated Financial Statements

30 June 2021

		For the six months ended	
		30 June	2020
		2021	2020
		RMB'000	'000
		(Unaudited)	(Unaudited)
REVENUE		16,877,537	13,001,100
Revenue from operations		(8,110,878)	(8,214,822)
Other income		8,766,659	11,430,300
Finance income		141,714	1,042,000
Finance costs		(4,356,975)	(3,310,000)
Share of profit of associates		(1,505,057)	(1,322,230)
Share of profit of joint ventures		(1,561,885)	(1,204,420)
Other income		(14,804)	(42,000)
Other income		1,645,255	1,032,200
Other income		(338,367)	(2,138,000)
Other income		116,605	43,000
Other income		(420,725)	(424,000)
Other income		(93,817)	(4,000)
Other income		925,626	1,100,400
PROFIT BEFORE TAX		3,304,229	2,301,100
Income tax expense	10	(550,647)	(3,200,000)
PROFIT FOR THE PERIOD		2,753,582	1,101,100
Profit attributable to ordinary equity holders of the parent		2,482,373	1,141,100
Profit attributable to non-controlling interests		271,209	140,000
PROFIT FOR THE PERIOD		2,753,582	1,101,100
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	12		
Basic earnings per share		RMB0.97 Yuan	0.40 Yuan
Diluted earnings per share		RMB0.97 Yuan	0.40 Yuan

Interim Condensed Consolidated

Income Statement

For the interim period ended 30 June 2021

	2021	2020
Revenue		
Cost of sales		
Operating expenses		
Operating profit		
Finance income		
Finance expense		
Share of profit of associates		
Profit before income tax		
Income tax expense		
Profit for the period		

Interim Condensed Consolidated

30 2021

		30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
NON-CURRENT ASSETS			
	13	11,986,909	12, 3
		2,574,667	2, ,402
		8,622,217	1, ,24
		9,730,364	, ,41
		349,077	3 1, 1
		22,447,860	21 0,
		6,243	1,043
		1,459,128	1,4 0,
		232,984	244, 3
		1,807,055	1,0 3, 24
		59,216,504	1, 44,320
CURRENT ASSETS			
	14	5,485,618	,1 2 00
		6,028,237	4 0, 0
		3,462,140	2, 4,1
		3,267,854	1, 0,0
		472,998	2 1 1
		10,489,133	, 1 02
		29,205,980	2 ,0 4 03
CURRENT LIABILITIES			
	1	3,745,584	3,2 0,21
		6,582,248	, , 4
	1	15,852,411	14,4 1, 4
		140,052	1 1,0 4
		1,447,288	1,020,30
		389,670	32 ,42
		28,157,253	24 2,3 3
NET CURRENT ASSETS		1,048,727	212,4 0
TOTAL ASSETS LESS CURRENT LIABILITIES		60,265,231	1, , 0

Interim Condensed Consolidated

30 June 2021

		30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
NON-CURRENT LIABILITIES			
1		8,513,509	1,400,000
		706,945	2,201
		2,935,378	2,201
		506,250	4,220
		277,854	2,400
		285,708	121,120
		13,225,644	12,201,340
Net assets		47,039,587	4,201,340
EQUITY			
Equity attributable to owners of the parent			
		2,562,899	2,201
		35,241,150	34,300,400
		37,804,049	3,301,400
Non-controlling interests		9,235,538	1,111,400
Total equity		47,039,587	4,201,340

Interim Condensed Consolidated

30 2021

	Attributable to owners of the parent									
	Share capital RMB'000	Share premium RMB'000	Fair value reserve RMB'000	Statutory surplus reserve RMB'000	Other reserve RMB'000	Exchange fluctuation reserve RMB'000	Retained profits RMB'000	Total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
1 2021 ()	2,562,899	11,385,162*	139,710*	2,728,604*	3,888,329*	(1,061,719)*	17,295,662*	36,938,647	8,988,749	45,927,396
	—	—	—	—	—	—	2,482,373	2,482,373	271,209	2,753,582
	—	—	2,698	—	—	—	—	2,698	1,722	4,420
	—	—	64,833	—	—	—	—	64,833	—	64,833
	—	—	—	—	—	(164,832)	—	(164,832)	(36,880)	(201,712)
	—	—	67,531	—	—	(164,832)	2,482,373	2,385,072	236,051	2,621,123
	—	—	—	—	(460,551)	—	—	(460,551)	(67,129)	(527,680)
	—	—	—	—	—	—	—	—	9,600	9,600
	—	—	—	—	—	—	—	—	169,710	169,710
	—	—	—	—	9,104	—	—	9,104	37,128	46,232
	—	—	—	—	(17,557)	—	—	(17,557)	—	(17,557)
	—	—	—	—	—	—	—	—	35,420	35,420
	—	—	—	—	—	—	—	—	(65,723)	(65,723)
	—	—	—	(2,449)	—	—	2,449	—	(175,821)	(175,821)
	—	—	—	—	—	—	—	—	58,179	58,179
	—	—	—	—	6,469	—	—	6,469	(4,166)	2,303
	—	—	—	—	45,862	—	—	45,862	13,540	59,402
2020 ()	—	—	—	—	—	—	(1,102,997)	(1,102,997)	—	(1,102,997)
30 2021 ()	2,562,899	11,385,162*	207,241*	2,726,155*	3,471,656*	(1,226,551)*	18,677,487*	37,804,049	9,235,538	47,039,587

* The amounts are subject to audit by the independent member of the audit firm. The amounts are subject to audit by the independent member of the audit firm. The amounts are subject to audit by the independent member of the audit firm.

Interim Condensed Consolidated

Interim Condensed Consolidated Financial Statements

		For the six months ended 30 June	
		2021	2020
		RMB'000	'000
		(Unaudited)	(Unaudited)
Operating profit		2,094,337	1,212,212
Finance income		(387,696)	(43,325)
Finance expense			
Profit before income tax		1,706,641	1,168,887
Income tax expense			
CASH FLOWS FROM INVESTING ACTIVITIES			
Acquisition of subsidiaries		(2,286,070)	(1,041,145)
Acquisition of intangible assets	1	(21,391)	(5,400)
Acquisition of property, plant and equipment		(100,172)	(1,243,100)
Acquisition of investment properties		(191,752)	(43,000)
Disposal of property, plant and equipment		537,242	1,100,000
Disposal of investment properties		80,764	44,444
Disposal of subsidiaries	1	237,609	
Disposal of intangible assets		61,154	1,000
Disposal of financial assets		8,009	1,000
Disposal of other assets		—	1,000
Disposal of other intangible assets		18,421	43
(Disposal of) / acquisition of financial assets		(12,392)	3,400
Disposal of other financial assets		—	22,000
Disposal of other intangible assets		(819,125)	(1,130,000)
Disposal of other assets		37,959	(42,300)
Cash flows from investing activities		(2,449,744)	(2,317,333)

Interim Condensed Consolidated

Financial Statement
For the interim period ended 30 June 2021

	For the six months ended	
	2021	2020
	RMB'000	'000
	(Unaudited)	(Unaudited)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from the issuance of bank loans	14,330,459	1,141,411
Repayment of bank loans	(12,723,895)	(4,311,311)
Repayment of interest on bank loans	(419,549)	(441,311)
Repayment of interest on other financial liabilities	(68,914)	(1,431)
Proceeds from the issuance of other financial liabilities	251,362	1,231
Proceeds from the issuance of equity	—	(2,241)
Proceeds from the issuance of debt securities	(69,024)	(1,411,311)
Proceeds from the issuance of other financial assets	(530,770)	(1,111)
Net increase in cash and cash equivalents	769,669	1,210,311
Effect of exchange rate changes on cash and cash equivalents	26,566	(10,311)
Net increase in cash and cash equivalents	7,324,881	1,244,311
Less: Cash and cash equivalents at the beginning of the period	(103,270)	(1,431)
Cash and cash equivalents at the end of the period	7,248,177	1,111,411
Analysis of balances of cash and cash equivalents:		
Cash	10,489,133	1,041
Cash equivalents	(3,240,956)	(1,311,311)
Total	7,248,177	1,111,411

4. OPERATING SEGMENT INFORMATION

本公司按照《企业会计准则第35号——分部报告》的规定披露分部信息。分部信息以内部组织结构为基础，按照业务类型、地区等进行划分。分部信息以内部报告为基础编制，与按照会计准则编制的财务报表存在差异。

- () 本公司按照《企业会计准则第35号——分部报告》的规定披露分部信息。分部信息以内部组织结构为基础，按照业务类型、地区等进行划分。分部信息以内部报告为基础编制，与按照会计准则编制的财务报表存在差异。
- () 本公司按照《企业会计准则第35号——分部报告》的规定披露分部信息。分部信息以内部组织结构为基础，按照业务类型、地区等进行划分。分部信息以内部报告为基础编制，与按照会计准则编制的财务报表存在差异。
- () 本公司按照《企业会计准则第35号——分部报告》的规定披露分部信息。分部信息以内部组织结构为基础，按照业务类型、地区等进行划分。分部信息以内部报告为基础编制，与按照会计准则编制的财务报表存在差异。
- () 本公司按照《企业会计准则第35号——分部报告》的规定披露分部信息。分部信息以内部组织结构为基础，按照业务类型、地区等进行划分。分部信息以内部报告为基础编制，与按照会计准则编制的财务报表存在差异。
- () 本公司按照《企业会计准则第35号——分部报告》的规定披露分部信息。分部信息以内部组织结构为基础，按照业务类型、地区等进行划分。分部信息以内部报告为基础编制，与按照会计准则编制的财务报表存在差异。

本公司按照《企业会计准则第35号——分部报告》的规定披露分部信息。分部信息以内部组织结构为基础，按照业务类型、地区等进行划分。分部信息以内部报告为基础编制，与按照会计准则编制的财务报表存在差异。

本公司按照《企业会计准则第35号——分部报告》的规定披露分部信息。分部信息以内部组织结构为基础，按照业务类型、地区等进行划分。分部信息以内部报告为基础编制，与按照会计准则编制的财务报表存在差异。

本公司按照《企业会计准则第35号——分部报告》的规定披露分部信息。分部信息以内部组织结构为基础，按照业务类型、地区等进行划分。分部信息以内部报告为基础编制，与按照会计准则编制的财务报表存在差异。

Notes to Interim Condensed Consolidated

30 June 2021

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2021 (unaudited)

	Pharmaceutical manufacturing RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare Service RMB'000	Pharmaceutical distribution and retail RMB'000	Other business operations RMB'000	Eliminations RMB'000	Total RMB'000
Segment revenue							
Revenue from sales to customers	12,179,257	2,832,211	1,843,434	—	22,635	—	16,877,537
Revenue from sales to other segments	13,233	17,779	20,501	—	12,639	(64,152)	—
Revenue	12,192,490	2,849,990	1,863,935	—	35,274	(64,152)	16,877,537
Segment results*							
Segment profit	1,352,891	434,099	(19,393)	—	9,266	(23,352)	1,753,511
Segment contribution	102,012	14,123	15,428	—	7,430	—	138,993
Segment operating expenses	201,990	2,283	87,416	—	262,270	(111,725)	442,234
Segment depreciation and amortization	85,180	16,516	14,508	—	1,698	(14,636)	103,266
Segment impairment losses	(80,436)	(13,698)	(25,545)	—	(5,312)	21,894	(103,097)
Segment other non-recurring gains and losses	(35,582)	(34,764)	(12,181)	—	(258,830)	—	(341,357)
Segment other non-recurring gains	(93,805)	—	—	—	(12)	—	(93,817)
Segment other non-recurring losses	35,707	90,143	(28,178)	896,991	(69,037)	—	925,626
Segment other non-recurring gains	—	—	—	—	—	—	478,870
Segment other non-recurring losses	1,567,957	508,702	32,055	896,991	(52,527)	(127,819)	3,304,229
Segment other non-recurring gains	(311,399)	(54,486)	(47,288)	—	(2)	—	(413,175)
Segment other non-recurring losses	—	—	—	—	—	—	(137,472)
Segment other non-recurring gains	1,256,558	454,216	(15,233)	896,991	(52,529)	(127,819)	2,753,582
Segment assets:	46,659,269	8,322,272	9,898,810	15,355,639	4,458,138	(2,668,056)	82,026,072
Segment property, plant and equipment	342,929	—	—	—	6,148	—	349,077
Segment intangible assets	2,273,758	555,078	1,589,874	15,355,639	2,673,511	—	22,447,860
Segment other non-current assets	—	—	—	—	—	—	6,396,412
Segment other non-current assets	—	—	—	—	—	—	88,422,484
Segment liabilities:	17,422,127	2,202,799	2,555,456	—	710,137	(10,426,621)	12,463,898
Segment other non-current liabilities	—	—	—	—	—	—	28,918,999
Segment other non-current liabilities	—	—	—	—	—	—	41,382,897
Other segment information:							
Segment other non-current assets	643,074	123,971	157,392	—	21,010	—	945,447
Segment other non-current liabilities	(1,288)	25,438	7,872	—	190,114	—	222,136
Segment other non-current liabilities	1,323,129	137,508	477,910	—	102,565	—	2,041,112

* Segment results are calculated based on the accounting policies of the Group. Segment results may differ from the results reported in the consolidated financial statements due to the elimination of inter-segment transactions and the recognition of inter-segment receivables and payables.

** Segment other non-current assets and liabilities include the amounts of the Group's other non-current assets and liabilities that are not directly attributable to the operating segments.

Notes to Interim Condensed Consolidated

30 June 2021

5. REVENUE

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 ()
Revenue from contracts with customer	16,864,028	13,141,811
Revenue from other operations	13,509	13,111
Total revenue	16,877,537	13,154,922

Disaggregated revenue information for revenue from contracts with customer

For the six months ended 30 June 2021 (unaudited)

Segments	Pharmaceutical manufacturing RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare service RMB'000	Other business operations RMB'000	Total RMB'000
Types of goods or services					
Pharmaceutical manufacturing	11,733,205	2,742,001	37,479	—	14,512,685
Medical devices and medical diagnosis	414,422	76,259	1,804,041	11,459	2,306,181
Healthcare service	30,599	13,951	612	—	45,162
Total	12,178,226	2,832,211	1,842,132	11,459	16,864,028
Geographical markets					
China	8,474,661	1,339,179	1,842,132	10,040	11,666,012
Overseas	3,703,565	1,493,032	—	1,419	5,198,016
Total	12,178,226	2,832,211	1,842,132	11,459	16,864,028
Timing of revenue recognition					
Contract revenue	11,763,804	2,755,952	38,091	—	14,557,847
Revenue from other operations	297,157	13,239	1,804,041	11,459	2,125,896
Revenue from other operations	117,265	63,020	—	—	180,285
Total	12,178,226	2,832,211	1,842,132	11,459	16,864,028

5. REVENUE (Continued)

Disaggregated revenue information for revenue from contracts with customers (Continued)

For the six months ended 30 June 2020 (unaudited)

	2020	2019	2020	2019	2020
	'000	'000	'000	'000	'000
Types of goods or services					
License fees	10,123	2,421,551	2,50		12,015,11
Product sales	23,34	1,01	1,331,14	3,2	1,11,20
Other services	3	1,014			3
Total	1,242	2,35,4	1,3,4	3,2	13,141
Geographical markets					
China	1,215	1,32,2	1,3,4	2,04	1,0,242
Other geographical markets	2,03	1,311,201		22	4,0,1,1
Total	1,242	2,35,4	1,3,4	3,2	13,141
Timing of revenue recognition					
At a point in time	0	2,43	2,50		12,134,210
Over time	21,01	1,0	1,331,14	3,2	1,11,001
Other	3	31,44			20
Total	1,242	2,35,4	1,3,4	3,2	13,141

Notes to Interim Condensed Consolidated

30 June 2021

6. OTHER INCOME

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 ()
Interest income	8,009	20,311
Dividend income	132,660	1,113
Other income	1,045	1,111
Total	141,714	1,042

7. OTHER GAINS

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 ()
Gain on disposal of subsidiaries	279,501	1,220
Gain on disposal of investments	1,182,759	23,344
Gain on disposal of property, plant and equipment	47,549	41,000
Gain on disposal of intangible assets	78,995	
Other gains	56,451	311
Total	1,645,255	3,222

8. FINANCE COSTS

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 ()
Interest expense	413,098	42,111
Finance charges	14,841	12,111
Finance income	(7,214)	(1,111)
Total	420,725	42,111

9. PROFIT BEFORE TAX

本集团利润总额(人民币千元)

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 ()
营业收入	6,433,620	4,32,00
营业成本	1,677,258	1,252,2
毛利(营业收入减去营业成本)	3,070,335	2,45,2
其他收益	180,142	43
公允价值变动收益	101,061	5,3
资产减值损失	39,619	3,1
利润总额	3,391,157	2,501
所得税费用	1,494,528	1,1,4
净利润	21,673	12,3
其他综合收益	564,429	40,4
公允价值变动收益	101,351	1,0
其他综合收益	279,667	24,24
利润总额()	16,953	(1)
其他综合收益	15,022	40,0
()/其他综合收益	(218)	2,5
净利润	190,379	
其他综合收益	(1,182,759)	(23,34)
其他综合收益	(47,549)	(41,05)
其他综合收益	(41,939)	(,1)
利润总额()	10,166	(1,21)

10. INCOME TAX

Income tax expense for the six months ended 30 June 2021 is RMB451,937 thousand (2020: RMB4,320 thousand). The effective tax rate for the six months ended 30 June 2021 is 2.1% (2020: 2.1%).

The income tax expense for the six months ended 30 June 2021 is primarily attributable to the income tax payable on the profit before tax of RMB21,500 thousand (2020: RMB20,500 thousand) at the statutory rate of 25% (2020: 25%).

The income tax expense for the six months ended 30 June 2021 is also affected by the following items:

- Income tax credit of RMB19,563 thousand (2020: RMB16,180 thousand) arising from the income tax credit for the six months ended 30 June 2021 (2020: RMB16,180 thousand).
- Income tax credit of RMB98,710 thousand (2020: RMB98,710 thousand) arising from the income tax credit for the six months ended 30 June 2021 (2020: RMB98,710 thousand).
- Income tax credit of RMB1,100 thousand (2020: RMB1,100 thousand) arising from the income tax credit for the six months ended 30 June 2021 (2020: RMB1,100 thousand).
- Income tax credit of RMB1,100 thousand (2020: RMB1,100 thousand) arising from the income tax credit for the six months ended 30 June 2021 (2020: RMB1,100 thousand).

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 (Audited)
Income tax expense	451,937	4,320
Income tax credit	98,710	(98,710)
Income tax expense	550,647	3,200

11. DIVIDENDS

On 11 June 2021, the Board of Directors of the Company has proposed a final dividend of RMB0.43 per share (2020: RMB0.43 per share) for the six months ended 30 June 2021. The dividend is subject to the approval of the shareholders at the general meeting of the Company.

12. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

本公司于2021年6月30日止六个月的归属于普通股股东的净利润(人民币千元)为2,482,373(2020年2,281,410)。

本公司于2021年6月30日止六个月的归属于普通股股东的净利润(人民币千元)为2,482,373(2020年2,281,410)。本公司于2021年6月30日止六个月的归属于普通股股东的净利润(人民币千元)为2,482,373(2020年2,281,410)。

本公司于2021年6月30日止六个月的归属于普通股股东的净利润(人民币千元)为2,482,373(2020年2,281,410)。

	For the six months ended 30 June	
	2021 RMB'000 (unaudited)	2020 '000 ()
Earnings		
归属于普通股股东的净利润	2,482,373	1,141,100
归属于普通股股东的净利润	2,482,373	1,141,100

	Number of shares For the six months ended 30 June	
	2021 (unaudited)	2020 ()
Shares		
归属于普通股股东的净利润	2,562,898,545	2,281,410
归属于普通股股东的净利润	2,562,898,545	2,281,410

本公司于2021年6月30日止六个月的归属于普通股股东的净利润(人民币千元)为2,482,373(2020年2,281,410)。

Notes to Interim Condensed Consolidated

30 June 2021

13. PROPERTY, PLANT AND EQUIPMENT

	For the six months ended	
	30 June	
	2021	2020
	RMB'000	'000
	(Unaudited)	()
Cost	12,579,873	10,200,000
Accumulated depreciation	1,481,681	1,111,240
Accumulated impairment losses	790	14,300
Accumulated depreciation and impairment losses	(46,840)	(133,000)
Net book value	(1,434,727)	(400,400)
Impairment losses	(564,429)	(400,400)
Impairment losses reversal	(29,439)	(4,300)
Net book value at 30 June	11,986,909	11,313,400

Impairment losses reversal of RMB1,434,727 thousand (2020: RMB400,400 thousand) was recognized in the consolidated income statement for the six months ended 30 June 2021.

14. TRADE AND BILLS RECEIVABLES

	30 June	
	2021	
	RMB'000	2020
	(Unaudited)	'000
	()	()
Trade receivables	5,989,288	4,000,000
Bills receivable	38,949	242,400
Total	6,028,237	4,242,400

Trade receivables are measured at amortized cost less expected credit losses. The impairment losses on trade receivables are recognized in the consolidated income statement.

14. TRADE AND BILLS RECEIVABLES (Continued)

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
Trade receivables	5,983,688	4,441,300
1. Trade receivables	144,645	1,300
2. Bills receivable	13,640	42,000
3. Other receivables	140,781	121,300
Provision for doubtful debts	(293,466)	(2,000)
	5,989,288	4,439,300
At 30 June 2021, the carrying amount of trade receivables is 4,300,000 (2020: 4,300,000)		

15. TRADE AND BILLS PAYABLES

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
Trade payables	3,208,429	2,420,000
Bills payable	537,155	34,300
	3,745,584	2,454,300

Notes to Interim Condensed Consolidated

30 June 2021

15. TRADE AND BILLS PAYABLES (Continued)

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
Trade payables	3,152,144	2,881,111
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100.	39,361	44,200
Trade bills payable	12,770	1,000
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100.	4,154	1,000
	3,208,429	2,420,111

16. INTEREST-BEARING BANK AND OTHER BORROWINGS

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
Bank borrowings	(1)	1,043,311
Other borrowings	1,302,115	1,243,311
	17,638,033	1,344,244
Bank borrowings	(2)	1,500,000
Other borrowings	(3)	5,227,887
	24,365,920	22,444,311
Bank borrowings	(15,852,411)	(14,411,411)
	8,513,509	8,032,900

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
1. Bank loans	15,852,411	14,411,4
2. Other borrowings	2,664,956	,42,33
3. Finance lease liabilities	4,226,672	2,3
4. Contract liabilities	1,621,881	,3
	24,365,920	22,4,31
Less: Contract liabilities	(15,852,411)	(14,411,4)
	8,513,509	,4,1

(1) Bank loans

	30 June 2021	31 December 2020
1. Bank loans	15,852,411	14,411,4
2. Other borrowings	2,664,956	,42,33
3. Finance lease liabilities	4,226,672	2,3
4. Contract liabilities	1,621,881	,3
	24,365,920	22,4,31
Less: Contract liabilities	(15,852,411)	(14,411,4)
	8,513,509	,4,1

(2) Super Short-term Commercial Paper

2. Super Short-term Commercial Paper	1,000,000,000	-
--------------------------------------	---------------	---

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

(continued)

(3) Corporate bonds

14	2018	1,200,000,000	4.0%	14	2022	1,200,000,000
13	2018	1,300,000,000	10%	13	2023	1,300,000,000
30	2018	1,000,000,000	4.4%	30	2023	1,000,000,000
2	2021	1,000,000,000	3.1%	2	2022	1,000,000,000

17. BUSINESS COMBINATION

2	2021	100%	(深圳信生藥業有限公司)
1	2021	0%	(上海星苑達醫療科技有限公司)

* 2021年6月30日，本公司收購了深圳信生藥業有限公司100%股權，收購成本為3,400,000元。

* 2021年6月30日，本公司收購了上海星苑達醫療科技有限公司0%股權，收購成本為22,400,000元。

17. BUSINESS COMBINATION (Continued)

		Fair value recognised on acquisition '000)
		2,800
		34,300
		,340
		,0
		(4,41)
		(,42)
		3,40
		(,00)
		2,800
		2,800
		'000)
		(12,0)
		,0
		(,81)
31 2020		(1,40)
		(21,31)

Notes to Interim Condensed Consolidated

30 June 2021

18. DISPOSAL OF SUBSIDIARIES (Continued)

	'000
Gain on disposal of subsidiaries	11,120
Gain on disposal of subsidiaries	34,3
Gain on disposal of subsidiaries	(10,04)
Gain on disposal of subsidiaries	23,0

19. COMMITMENTS

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
Commitments	2,334,273	2,244
Commitments	834,921	10,3
Commitments	498,805	342,1
Commitments	3,193,706	4,003,22
Commitments	6,861,705	12,10

20. RELATED PARTY TRANSACTIONS

(a) Sales of pharmaceutical products and services

	For the six months ended	
	2021	2020
	RMB'000	'000
	(Unaudited)	(Unaudited)
Product sales to related parties (Note 4 & 6 & 15)	1,809,891	1,333,332
Product sales to related parties (Note 1 & 4 & 16)	326,501	1,111,333
Product sales to related parties (Note 1 & 4)	7,936	4,030
Product sales to related parties (Note 1 & 4)	5,139	—
Product sales to related parties (Note 1 & 4)	2,436	—
Product sales to related parties (Note 1 & 4 & 6)	2,039	3
Product sales to related parties (Note 2 & 4)	2,030	14
Product sales to related parties (Note 1 & 4)	1,251	1,000
Product sales to related parties (Note 2 & 4)	671	40
Product sales to related parties (Note 1 & 4)	637	2,000
Product sales to related parties (Note 3 & 4 & 10 & 16)	252	1,000
Product sales to related parties (Note 4 &)	148	4,310
Product sales to related parties (Note 4 &)	40	4,410
Product sales to related parties (Note 1 & 4)	26	13
Product sales to related parties (Note 4 & 7)	19	1
Product sales to related parties (Note 1 & 4)	6	1,000
Product sales to related parties (Note 4 &)	6	1
Product sales to related parties (Note 4 &)	4	42
Product sales to related parties (Note 1 & 4)	3	3
Product sales to related parties (Note 1 & 4)	—	2,000
Product sales to related parties (Note 4 &)	—	303
Product sales to related parties (Note 2 & 4 & 17)	—	1,120
Product sales to related parties (Note 1 & 4)	—	1,220
	2,159,035	1,220,000

20. RELATED PARTY TRANSACTIONS (Continued)

(b) Purchase of pharmaceutical products and services

The table content is completely redacted with a large blue rectangle. A horizontal line is visible at the bottom of the redacted area, indicating the table structure.

20. RELATED PARTY TRANSACTIONS (Continued)

(c) Leasing and property management services (Continued)

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000
As lessee		
Leasing services (3 & 5 & 13 & 16)	5,242	2, 2
Property management services (5 &)	114	11
Other services (5 &)	41	43
	5,397	3,112

	For the six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000
Property management services		
Property management services (3 & 5 & 14 & 16)	6,818	, 04

(d) Loans from/to a related parties

	30 June	
	2021 RMB'000 (Unaudited)	2020 '000
Deposits in Fosun Finance		
Deposits in Fosun Finance (3 & 16)	965,024	44 , 0

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
A loan from a related party		
Loans from related parties (Notes 3 & 16)	73,450	1,300
<p>On 14 June 2021, the Group obtained a loan of RMB14,000 from a related party at an interest rate of 3% per annum.</p> <p>On 11 June 2021, the Group obtained a loan of RMB40,000 from a related party at an interest rate of 10% per annum.</p> <p>On 3 June 2021, the Group obtained a loan of RMB3,400,000 from a related party at an interest rate of 3.4% per annum.</p> <p>On 4 June 2021, the Group obtained a loan of RMB4,211,000 from a related party at an interest rate of 3.4% per annum.</p>		
Loans to related parties		
Loans to related parties (Notes 1 & 2)	202,345	1,300
<p>Loans to related parties (Notes 1 & 2)</p>	5,814	1,300
Loans to related parties (Notes 1 & 2)	188,840	1,300
Loans to related parties (Notes 1 & 2)	7,691	1,300

(e) Interest income from/interest expense to related parties

	Six months ended 30 June 2021 RMB'000 (Unaudited)	2020 '000 ()
Interest income		
Interest income from related parties (Notes 1 & 2)	4,678	4,000
Interest income from related parties (Notes 3 & 16)	4,560	3,300
Interest income from related parties (Notes 1 & 2)	182	1,000
Interest income from related parties (Notes 1 & 2)	112	1,000
	9,532	9,300

20. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/interest expense to related parties (continued)

0.3% (2020 0.3%),
 1.1% (2020 1.1%),
 1.1% (2020 1.1%),
 3.4% (2020 3.4%).

	Six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000
Interest expense		
(3 & 16)	1,432	1,015

- (1) 2021年6月30日，本公司应收关联方款项余额为人民币1,432,000元，其中应收关联方账款余额为人民币1,432,000元。
- (2) 2021年6月30日，本公司应付关联方款项余额为人民币1,015,000元，其中应付关联方账款余额为人民币1,015,000元。
- (3) 2021年6月30日，本公司应收关联方款项余额为人民币1,432,000元，其中应收关联方账款余额为人民币1,432,000元。
- (4) 2021年6月30日，本公司应付关联方款项余额为人民币1,015,000元，其中应付关联方账款余额为人民币1,015,000元。
- (5) 2021年6月30日，本公司应收关联方款项余额为人民币1,432,000元，其中应收关联方账款余额为人民币1,432,000元。
- (6) 2021年6月30日，本公司应付关联方款项余额为人民币1,015,000元，其中应付关联方账款余额为人民币1,015,000元。
- (7) 2021年6月30日，本公司应收关联方款项余额为人民币1,432,000元，其中应收关联方账款余额为人民币1,432,000元。
- (8) 2021年6月30日，本公司应付关联方款项余额为人民币1,015,000元，其中应付关联方账款余额为人民币1,015,000元。
- (9) 2021年6月30日，本公司应收关联方款项余额为人民币1,432,000元，其中应收关联方账款余额为人民币1,432,000元。
- (10) 2021年6月30日，本公司应付关联方款项余额为人民币1,015,000元，其中应付关联方账款余额为人民币1,015,000元。
- (11) 2021年6月30日，本公司应收关联方款项余额为人民币1,432,000元，其中应收关联方账款余额为人民币1,432,000元。

20. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/interest expense to related parties (continued)

(continued)

(12)	Interest income from related parties	14,000	14,000
(13)	Interest expense to related parties	(14,000)	(14,000)
(14)	Interest income from related parties	14,000	14,000
(1)	Interest expense to related parties	(14,000)	(14,000)
(1)	Interest income from related parties	14,000	14,000
(1)	Interest expense to related parties	(14,000)	(14,000)

(f) Compensation of key management personnel of the Group

	Six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 (Audited)
Salaries and bonuses	49,724	0,011
Short-term employee benefits	17,451	1,410
Retirement benefits	526	243
Total	67,701	1,664

(g) Guarantees

	Guarantee amount	Start date	End date	Fulfilled or not
Guarantee for related party	10 ⁵ , 2,000	2021/ /22	2021/12/2	
Guarantee for related party	43, 0 ,000	2021/ /1	2021/12/2	

20. RELATED PARTY TRANSACTIONS (Continued)

(h) Donations

	Six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000
	8,708	1,000

As at 30 June 2021, the amount of donations is RMB1,000,000 (30 June 2020: RMB1,000,000).

(i) Outstanding balances with related parties:

() As at 30 June 2021, the amount of outstanding balances with related parties is RMB1,322,200 (31 December 2020: RMB4,340,000). The amount of outstanding balances with related parties is RMB1,322,200 (31 December 2020: RMB4,340,000).

() As at 30 June 2021, the amount of outstanding balances with related parties is RMB1,000,230 (31 December 2020: RMB1,200,000). The amount of outstanding balances with related parties is RMB1,000,230 (31 December 2020: RMB1,200,000).

() As at 30 June 2021, the amount of outstanding balances with related parties is RMB1,214,000 (31 December 2020: RMB1,214,000). The amount of outstanding balances with related parties is RMB1,214,000 (31 December 2020: RMB1,214,000).

() As at 30 June 2021, the amount of outstanding balances with related parties is RMB4,041,000 (31 December 2020: RMB2,000,000). The amount of outstanding balances with related parties is RMB4,041,000 (31 December 2020: RMB2,000,000).

() As at 30 June 2021, the amount of outstanding balances with related parties is RMB1,440,000 (31 December 2020: RMB132,000). The amount of outstanding balances with related parties is RMB1,440,000 (31 December 2020: RMB132,000).

() As at 30 June 2021, the amount of outstanding balances with related parties is RMB23,230 (31 December 2020: RMB300,300). The amount of outstanding balances with related parties is RMB23,230 (31 December 2020: RMB300,300).

() As at 30 June 2021, the amount of outstanding balances with related parties is RMB43,000 (31 December 2020: RMB44,000). The amount of outstanding balances with related parties is RMB43,000 (31 December 2020: RMB44,000).

() As at 30 June 2021, the amount of outstanding balances with related parties is RMB13,000 (31 December 2020: RMB10,300). The amount of outstanding balances with related parties is RMB13,000 (31 December 2020: RMB10,300).

20. RELATED PARTY TRANSACTIONS (Continued)

(i) Outstanding balances with related parties: (Continued)

()

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

	Carrying amounts		Fair values	
	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()	30 June 2021 RMB'000 (Unaudited)	31 2020 '000 ()
Financial Assets:				
Financial assets at fair value through profit or loss	6,243	1,043	6,243	1,043
Financial assets at fair value through other comprehensive income	472,998	2,411	472,998	2,411
Financial assets at fair value through profit or loss	4,726,982	3,430	4,726,982	3,430
Financial assets at fair value through profit or loss	294,076	1,140	297,354	1,140
	5,500,299	4,242	5,503,577	4,242
Financial liabilities:				
Financial liabilities at fair value through profit or loss	6,674,021	14,114	6,694,426	12,111
Financial liabilities at fair value through profit or loss	5,227,887	3,2010	5,195,438	3,3003
Financial liabilities at fair value through profit or loss	248,335	241,3	248,335	241,3
Financial liabilities at fair value through profit or loss	71,200	3,03	71,200	3,03
	12,221,443	14,012	12,209,399	14,103

Notes to Interim Condensed Consolidated

30 June 2021

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Unobservable inputs for Level 3 liabilities

At 30 June 2021	1,200,000 (31 June 2020)
At 30 June 2020	3,033,000 (31 June 2019)

Fair value hierarchy

The following table shows the fair value hierarchy of the assets and liabilities measured at fair value:

Assets measured at fair value:

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
At 30 June 2021				
Financial assets	3,017,461	206,237	1,503,284	4,726,982
Financial liabilities	—	6,243	—	6,243
Non-financial assets	—	472,998	—	472,998
Total	3,017,461	685,478	1,503,284	5,206,223
At 31 June 2020				
Financial assets	1,213,411	101,310	1,140,210	3,430,000
Financial liabilities	—	1,043	—	1,043
Non-financial assets	—	2,881	—	2,881
Total	1,213,411	1,331,310	1,140,210	4,000,000

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Assets measured at fair value: (Continued)

30 2021		Financial assets at fair value through profit and loss RMB'000 (Unaudited)	Equity investments Designated at fair value through other comprehensive income RMB'000 (Unaudited)
1 2021		1,514,028	—
11 2021		(159,575)	—
11 2021		(9,123)	—
11 2021		191,582	—
11 2021		(33,628)	—
30 2021		1,503,284	—
30 2020			
1 2020		1,224	324
11 2020		114	—
11 2020		—	24
11 2020		13	—
11 2020		(321)	—
11 2020		21	—
30 2020		1,400	30

As at 30 September 2021, the fair value of financial assets at fair value through profit and loss is RMB1,503,284,000 (RMB1,400,000,000 as at 30 September 2020). The fair value of equity investments designated at fair value through other comprehensive income is RMB— (RMB30,000 as at 30 September 2020).

Notes to Interim Condensed Consolidated

30 June 2021

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Liabilities measured at fair value:

	Fair value measurement using			Total RMB'000
	Quoted prices in active Markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
As at 30 June 2021 (RMB'000)	—	—	71,200	71,200
As at 31 December 2020 (RMB'000)	(1,000)	(1,200)	(1,300)	(3,500)
As at 30 June 2020 (RMB'000)	—	—	3,003	3,003

	Six months ended 30 June	
	2021 RMB'000 (Unaudited)	2020 '000 (Audited)
As at 1 January	73,503	2,411,244
Change during the period	(2,303)	3,02
As at 30 June	71,200	(20,244)

The fair value of the liabilities is determined using the market value of the liabilities as at the reporting date. The fair value of the liabilities is determined using the market value of the liabilities as at the reporting date.

Definitions

<p>「中國證監會」指中國證券監督管理委員會，其辦事處設於北京，為中國政府監管證券市場之主要機構。</p>	<p>* (中國證券監督管理委員會)，其辦事處設於北京，為中國政府監管證券市場之主要機構。</p>
<p>「()」指「()」。</p>	<p>()指「()」。</p>
<p>「遠東」指遠東食品集團有限公司，其股份在聯交所上市。</p>	<p>* (遠東腸衣食品有限公司)</p>
<p>「佛山復星禪誠醫院有限公司」指佛山復星禪誠醫院有限公司，其股份在聯交所上市。</p>	<p>* (佛山復星禪誠醫院有限公司)，其股份在聯交所上市。</p>
<p>「佛山禪城區中心醫院有限公司」指佛山禪城區中心醫院有限公司，其股份在聯交所上市。</p>	<p>* (佛山市禪城區中心醫院有限公司)，其股份在聯交所上市。</p>
<p>「佛山禪城區人口和衛生藥品監督管理局」指佛山禪城區人口和衛生藥品監督管理局，其辦事處設於佛山。</p>	<p>(佛山市禪城區人口和衛生藥品監督管理局)，其辦事處設於佛山。</p>
<p>「佛山禪曦房地產開發有限公司」指佛山禪曦房地產開發有限公司，其股份在聯交所上市。</p>	<p>* (佛山禪曦房地產開發有限公司)</p>
<p>「上海復星醫療系統有限公司」指上海復星醫療系統有限公司，其股份在聯交所上市。</p>	<p>* (上海復星醫療系統有限公司)，其股份在聯交所上市。</p>
<p>「上海復星健康科技(集團)有限公司」指上海復星健康科技(集團)有限公司，其股份在聯交所上市。</p>	<p>* (上海復星健康科技(集團)有限公司)，其股份在聯交所上市。</p>
<p>「上海復星醫療(集團)有限公司」指上海復星醫療(集團)有限公司，其股份在聯交所上市。</p>	<p>* (上海復星醫療(集團)有限公司)，其股份在聯交所上市。</p>
<p>「上海復星高科技(集團)有限公司」指上海復星高科技(集團)有限公司，其股份在聯交所上市。</p>	<p>* (上海復星高科技(集團)有限公司)，其股份在聯交所上市。</p>
<p>「復星國際」指復星國際有限公司，其股份在聯交所上市。</p>	<p>(復星國際有限公司)，其股份在聯交所上市。</p>
<p>「復星國際控股有限公司」指復星國際控股有限公司，其股份在聯交所上市。</p>	<p>(復星國際控股有限公司)，其股份在聯交所上市。</p>
<p>「復星國際有限公司」指復星國際有限公司，其股份在聯交所上市。</p>	<p>(復星國際有限公司)，其股份在聯交所上市。</p>
<p>「復星凱特生物科技有限公司」指復星凱特生物科技有限公司，其股份在聯交所上市。</p>	<p>* (復星凱特生物科技有限公司)，其股份在聯交所上市。</p>
<p>「上海復星醫藥產業發展有限公司」指上海復星醫藥產業發展有限公司，其股份在聯交所上市。</p>	<p>* (上海復星醫藥產業發展有限公司)，其股份在聯交所上市。</p>

...	... * (深圳信生藥業有限公司),
...	... * (廣東匯信藥業有限公司),
...	... * (國藥產業投資有限公司),
...	... * (國藥控股股份有限公司),
...	... (010)
...	... (01)
...	...
...	...
...	...
...	...
...	... * (宿遷市鐘吾醫院有限責任公司)/
...	... * (宿遷市腫瘤醫院),
...	... * (台州市投資有限公司)
...	... * (台州浙東醫養投資管理有限公司)
...	...
...	...
...	...
...	...
...	...
...	... * (江蘇萬邦雲健康科技有限公司),
...	... * (江蘇萬邦生化醫藥集團有限責任公司),
...	... * (瀋陽萬邦天晟生物科技有限公司),
...	...
...	... * (《董事/有關僱員進行證券交易的書面指引》)

Definitions

... (武漢濟和醫院有限公司), ...

... (上海星苑達醫療科技有限公司), ...

... (徐州星晨婦兒醫院有限公司), ...

... (重慶藥友製藥有限責任公司), ...

... (上海豫園旅遊商城(集團)股份有限公司), ... (00)

...